TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00532220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate IV
Description: Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
Study: NCT01052233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial meniscectomy
Description: Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopy (diagnostic)
Description: Diagnostic arthroscopy of the knee
Study: NCT00473811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low GI
Description: low-GI education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADA diet
Description: ADA dietary education
Study: NCT02678091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound exam with Doppler
Description: Ultrasound exam of the orbit
Study: NCT02952768

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ultrasound training
Description: Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
Study: NCT04563559

Intervention type: DRUG
Group type: OTHER
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Description: The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
Study: NCT02230358

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regional anesthesia
Description: Regional anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anesthesia
Description: General anesthesia

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler ultrasonography
Description: 6x for 4 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler ultrasonography
Description: 6x for 4 hours

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood gas analysis
Description: 6 x 3 ml blood withdrawal (18 ml) within 4 hours

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood gas analysis
Description: 6 x 3 ml blood withdrawal (18 ml) within 4 hours

Intervention type: PROCEDURE
Group type: OTHER
Intervention: invasive arterial blood pressure measurement
Description: before operation, 8 hours, as done in clinical routine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: invasive arterial blood pressure measurement
Description: before operation, 8 hours, as done in clinical routine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arterial blood gas measurement
Description: perioperative, 4-6 times within 8 hours, as done in clinical routine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arterial blood gas measurement
Description: perioperative, 4-6 times within 8 hours, as done in clinical routine
Study: NCT02010216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg by intravenous infusion every 4 weeks
Study: NCT01769417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4893
Description: Human immunoglobulin G1 kappa monoclonal antibody
Study: NCT02438995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial Cetxuimab (Erbitux)
Description: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial Cetxuimab (Erbitux)
Description: Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
Study: NCT02364167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan
Study: NCT02771249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentene (RPT)
Description: RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat (DRV/c)
Description: DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Study: NCT00532961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% and tobramycin 0.3%
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% and tobramycin 0.3%
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
Study: NCT02170805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS capsule formulation A
Description: BIBR 1048 MS, formulation A 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS capsule formulation B
Description: BIBR 1048 MS, formulation B 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS powder plus solution
Description: BIBR 1048 MS, powder plus solution 50 mg
Study: NCT02230358

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurological Control
Description: perioperative, 2-3 days, as done in clinical routine

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurological Control
Description: perioperative, 2-3 days, as done in clinical routine

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS monitoring
Description: perioperative, for 5 hours, as done in clinical routine

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIRS monitoring
Description: perioperative, for 5 hours, as done in clinical routine

Intervention type: DEVICE
Group type: OTHER
Intervention: oxygen supply (not invasive 'Vigileo')
Description: perioperative for 5 hours, as done in clinical routine

Intervention type: DEVICE
Group type: OTHER
Intervention: oxygen supply (not invasive 'Vigileo')
Description: perioperative for 5 hours, as done in clinical routine
Study: NCT02171663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study: NCT04421391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QuadraMune(TM)
Description: QuadraMune(TM) is a commercially available nutritional supplement
Study: NCT00595205

Intervention type: OTHER
Intervention: Hospital log review.
Description: Reviewing of the hospital log to monitor for the occurrence of intussusception.
Study: NCT03450096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LPB
Description: A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
Study: NCT03197246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVECG
Description: Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
Study: NCT01282944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Network
Description: Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Network
Description: Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
Study: NCT03752398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb®23104
Description: Monoclonal bispecific antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yervoy® (ipilimumab)
Description: Monoclonal antibody
Study: NCT02675959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
Study: NCT01726127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli and Brussels Sprouts

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cruciferous Complete

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02997657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: Exercises designed to boost moods, positive behaviors, and positive cognitions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation counseling
Description: Counseling designed to provide support and problem solving for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation counseling
Description: Counseling designed to provide support and problem solving for smoking cessation
Study: NCT02453633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional SMS text
Description: SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard SMS text
Description: SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS.
Study: NCT02716350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-GOS
Description: comparison versus placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: placebo
Study: NCT00256776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (Bortezomib)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02244749

Intervention type: OTHER
Intervention: skin specimen
Description: skin specimen
Study: NCT02947620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/Atorvastatin 1500mg/40mg, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1500mg, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 40mg, QD
Study: NCT04211519

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sampling
Description: sampling from endodontically infected primary and permanent teeth by using paper point method

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sampling
Description: sampling from endodontically infected primary and permanent teeth by using paper point method
Study: NCT03679273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Abound
Description: Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
Study: NCT00831025

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous monthly administration
Study: NCT04517929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy
Description: 9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
Study: NCT00672646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 95mg, oral solution, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500mg, capsule, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AZD1386 Placebo oral solution
Study: NCT01552993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol mixture 20 mg/kg + pacifier and glucose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: pacifier and sucrose
Study: NCT01981980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Description: Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
Study: NCT00191139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
Study: NCT01174524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gestoden 60 mcg
Description: gestoden 60 mcg, once a day, administered in 24/4 regimen.
Study: NCT00191139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
Study: NCT01174524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinylestradiol 15 mcg
Description: ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
Study: NCT00191139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
Study: NCT00991718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 oral capsules (non-labeled)
Description: 150 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 oral capsules (non-labeled)
Description: 150 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 oral capsules (non-labeled)
Description: 150 mg oral capsule
Study: NCT06748287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iGrow Hair Growth System
Description: has a helmet-design and headphones to allow for hands-free use and music listening capabilities. Treatment is 25 minutes every other day. three to four times per week for 4 months.
Study: NCT00991718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 IV injection (labeled)
Description: 10 mcg (in 2 mL) IV dose of 14C-GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449 IV injection (labeled)
Description: 10 mcg (in 2 mL) IV dose of 14C-GDC-0449
Study: NCT06748287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capillus352
Description: has a similar design to a salon hair dryer which hovers over the head to allow for hand-free use. Treatment is 12 minutes, three times per week for 4 months.
Study: NCT00991718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDC-0449 oral suspension (labeled)
Description: 30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDC-0449 oral suspension (labeled)
Description: 30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
Study: NCT06748287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HairMax Ultima 12 Lasercomb
Description: is comb-like device with hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 8 minutes three times per week for 4 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HairMax Laserband 82
Description: is headband design device which has unique hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 90-second treatments three times per week for 4 months.
Study: NCT00958386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab+irinotecan
Description: Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days.
Study: NCT03400488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 oral suspension
Description: In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
Study: NCT00027560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours.
Study: NCT00317512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Revascularization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Revascularization
Study: NCT03400488

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching AZD5817 oral suspension
Description: In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
Study: NCT00317512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Revascularization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)